PDF(1249 KB)
儿童系统性红斑狼疮合并肺高压15例临床分析
李冀, 马菁苒, 孙之星, 姜静婧, 董艳青, 王迁, 宋红梅
中国当代儿科杂志 ›› 2017, Vol. 19 ›› Issue (6) : 658-662.
PDF(1249 KB)
PDF(1249 KB)
儿童系统性红斑狼疮合并肺高压15例临床分析
A clinical analysis of 15 children with systemic lupus erythematosus accompanied by pulmonary hypertension
目的 探讨系统性红斑狼疮（SLE）合并肺高压（PH）患儿的临床和实验室检查特点、诊断治疗及预后。方法 选取住院诊断SLE合并PH（SLE-PH）的儿童患者15例，对其临床症状、实验室检查、超声心动图特点、SLE病情活动指标和治疗转归等进行回顾性分析。结果 15例SLE-PH患儿中，从SLE确诊到PH诊断的间隔时间中位数为0.1年（范围：0~6.5年）。除PH相关症状外，40%的患儿合并雷诺现象。反映SLE疾病活动度的指标（如补体C3、C4、ESR水平及抗dsDNA阳性率）在PH轻-中度组与重度组间比较差异无统计学意义。13例患儿接受糖皮质激素及免疫抑制剂治疗，2例同时接受PH靶向药物等治疗。诊断PH后，中位随访时间8.0年（范围：0.5~18.1年），期间2例患儿死亡，其心功能为Ⅲ~Ⅳ级；余13例病情平稳。结论 雷诺现象是SLE-PH患儿常见的临床表现。PH轻重程度与SLE疾病活动度无明显关联，应重视SLE患儿肺动脉压筛查。早期诊断、早期治疗有利于改善患儿预后。
Objective To evaluate the clinical features, laboratory findings, diagnosis and treatment, and prognosis of children with systemic lupus erythematosus (SLE) accompanied by pulmonary hypertension (PH). Methods The clinical symptoms, laboratory findings, echocardiographic features, SLE disease activity index, and treatment outcome of 15 hospitalized children with SLE accompanied by PH were retrospectively analyzed. Results Among the 15 patients, the median interval from diagnosis of SLE to diagnosis of PH was 0.1 year (range:0-6.5 years). Aside from PH-related symptoms, Raynaud's phenomenon was observed in 6 (40%) of the 15 patients. There was no significant difference in SLE disease activity (evaluated by complements 3 and 4 levels, erythrocyte sedimentation rate, and positive rate of anti-double-stranded DNA) between patients with mild-to-moderate PH and those with severe PH (P < 0.05). As for treatment, 13 patients received immunosuppressive therapy with glucocorticoids, and among them 2 patients received PH-targeted therapy. During a median follow-up of 8.0 years (range:0.5-18.1 years) since the diagnosis of PH, 2 deaths were noted with class III or IV cardiac function (World Health Organization), while the other patients were in a stable condition. Conclusions Raynaud's phenomenon is a common clinical manifestation in children with SLE accompanied by pulmonary hypertension (PH). PH severity is not significantly associated with SLE disease activity, and thus greater focus should be placed upon early screening of pulmonary arterial pressure in SLE patients. Early diagnosis and early treatment can improve the prognosis of children with SLE.
Systemic lupus erythematosus / Pulmonary hypertension / Raynaud's phenomenon / Child
[1] Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension[J]. J Am Coll Cardiol, 2013, 62(25 Suppl):D42-D50.
[2] Ruiz-Irastorza G, Garmendia M, Villar I, et al. Pulmonary hypertension in systemic lupus erythematosus:prevalence, predictors and diagnostic strategy[J]. Autoimmun Rev, 2013, 12(3):410-415.
[3] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997, 40(9):1725.
[4] Cossío-Aranda J, Zamora KD, Nanda NC, et al. Echocardiographic correlates of severe pulmonary hypertension in adult patients with ostium secundum atrial septal defect[J]. Echocardiography, 2016, 33(12):1891-1896.
[5] Konstantinides S, Geibel A, Olschewski M, et al. A comparison of surgical and medical therapy for atrial septal defect in adults[J]. N Engl J Med, 1995, 333(8):469-473.
[6] Xia YK, Tu SH, Hu YH, et al. Pulmonary hypertension in systemic lupus erythematosus:a systematic review and analysis of 642 cases in Chinese population[J]. Rheumatol Int, 2013, 33(5):1211-1217.
[7] Li M, Wang Q, Zhao J, et al. Chinese SLE Treatment and Research group (CSTAR) registry:II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus[J]. Lupus, 2014, 23(10):1085-1091.
[8] 王迁, 李梦涛, 曾小峰, 等. 系统性红斑狼疮相关肺动脉高压的诊治共识[J]. 中国临床医生杂志, 2015, 43(7):10-12.
[9] Anuardo P, Verdier M, Gormezano NW, et al. Subclinical pulmonary in childhood systemic lupus erythematosus associated with minor disease manifestations[J]. Pediatr Cardiol, 2017, 38(2):234-239.
[10] 邢燕, 宋红梅, 吴晓燕, 等. 小儿结缔组织病并发的肺动脉高压临床分析[J]. 中华儿科杂志, 2008, 46(11):822-826.
[11] 宋红梅, 魏珉. 儿童结缔组织病相关性肺动脉高压的诊断与治疗[J]. 中华儿科杂志, 2008, 46(11):847-850.
[12] Fei Y, Shi X, Gan F, et al. Death causes and pathogens analysis of systemic lupus erythematosus during the past 26 years[J]. Clin Rheumatol, 2014, 33(1):57-63.
[13] Huang C, Li M, Liu Y, et al. Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients[J]. Medicine (Baltimore), 2016, 95(10):e2761.
[14] Kasparian A, Floros A, Gialafos E, et al. Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus[J]. Lupus, 2007, 16(7):505-508.
[15] Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension[J]. Chest, 2012, 141(1):210-221.
[16] Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling[J]. J Am Coll Cardiol, 2009, 54(1 Suppl):S10-S19.
[17] Akdogan A, Kilic L, Dogan I, et al. Pulmonary hypertension in systemic lupus erythematosus:pulmonary thromboembolism is the leading cause[J]. J Clin Rheumatol, 2013, 19(8):421-425.
[18] Takatsuki S, Soep JB, Calderbank M, et al. Connective tissue disease presenting with signs and symptoms of pulmonary hypertension in children[J]. Pediatr Cardiol, 2011, 32(6):828-833.
[19] Huggins JL, Holland MJ, Brunner HI. Organ involvement other than lupus nephritis in childhood-onset systemic lupus erythematosus[J]. Lupus, 2016, 25(8):857-863.
[20] Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension[J]. Rev Esp Cardiol (Engl Ed), 2016, 69(2):177.
[21] Kommireddy S, Bhyravavajhala S, Kurimeti K, et al. Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy:an observational study[J]. Rheumatology (Oxford), 2015, 54(9):1673-1679.
[22] Prabu A, Gordon C. Pulmonary arterial hypertension in SLE:what do we know?[J]. Lupus, 2013, 22(12):1274-1285.
[23] Sitbon O, Jaïs X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension:a pilot study[J]. Eur Respir J, 2014, 43(6):1691-1697.
[24] Galiè N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study):a double-blind, randomised controlled trial[J]. Lancet, 2008, 371(9630):2093-2100.
[25] Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension[J]. N Engl J Med, 2002, 346(12):896-903.
[26] Chow SL, Chandran V, Fazelzad R, et al. Prognostic factors for survival in systemic lupus erythematosus associated pulmonary hypertension[J]. Lupus, 2012, 21(4):353-364.
[27] 周广宇, 梁薇薇, 刘锋. 系统性红斑狼疮合并肺动脉高压38例临床分析[J]. 中华风湿病学杂志, 2009, 13(8):552-554.
